NeuroMetrix Appoints Brad Fluegel to its Board of Directors
NeuroMetrix, Inc. (Nasdaq: NURO) today announced the appointment of
Bradley M. Fluegel to its Board of Directors, effective as of July
Mr. Fluegel has a broad commercial and advisory background with
concentrated industry experience in healthcare and medical
technology. He has held numerous leadership roles over the past 25+
years, primarily in healthcare strategy and business development.
Most recently, Mr. Fluegel was Senior Vice President, Chief
Healthcare Commercial Market Development Officer for Walgreens Co.
In this role he was responsible for leading all commercial
healthcare activities, including sales and contracting, biopharma
relationships, retail clinics, clinical affairs, new service
development and market planning. Prior to this role, he served as
Walgreens’ Chief Strategy and Business Development officer. Mr.
Fluegel is a senior advisor to Walgreens.
Previously, Mr. Fluegel was executive in residence at Health
Evolution Partners. Earlier in his career, he was Executive Vice
President, Chief Strategy and External Affairs Officer at Wellpoint
(now Elevance Health), Senior Vice President of National Accounts
and Vice President, Enterprise Strategy at Aetna, CEO for Reden
& Anders (Optum Consulting) and principal at Tillinghast-Towers
Perrin, a clinical, actuarial and management consulting practice
serving the health care industry.
Mr. Fluegel currently serves on the Boards of Directors of
Performant Financial Corporation, Premera Blue Cross, AdhereHealth
and the Metropolitan Jewish Health System in New York City. Mr.
Fluegel was also on the Boards of Fitbit and Itamar Medical, both
Nasdaq traded companies, until they were recently acquired. Mr.
Fluegel earned a master’s degree in public policy from Harvard
University and a bachelor’s degree in business administration from
the University of Washington. He is a lecturer in the Health Care
Management Department at the Wharton School of the University of
“We are pleased to welcome Brad to the NeuroMetrix Board of
Directors,” said Shai N. Gozani, M.D., Ph.D., Chairman and Chief
Executive Officer. "His extensive strategic and operational
experience in value-based care, medical technology, digital health
and overall thought leadership in healthcare aligns well with the
key elements of our growth strategy. “We look forward to working
closely with Brad and leveraging his leadership and insights for
the benefit of the Company.”
“NeuroMetrix presents the exciting challenge of a commercial
stage company with unique products that address large and important
unmet needs in the areas of neurology and chronic pain,” said Mr.
Fluegel. “I look forward to working with the NeuroMetrix team as
the company grows and continues to positively impact the lives of
individual patients and more broadly, population health."
NeuroMetrix is an innovation-driven company with a mission to
improve individual and population health through innovative medical
devices and technology solutions for neurological disorders and
pain syndromes. The Company has three commercial products.
DPNCheck® is a diagnostic device that provides rapid, point-of-care
detection of peripheral neuropathies. ADVANCE® is a diagnostic
device that provides automated, in-office nerve conduction studies
for the evaluation of focal neuropathies. Quell® is a wearable
neuromodulation technology indicated for treatment of fibromyalgia
symptoms and chronic lower extremity pain. For more information,
Source: NeuroMetrix, Inc.Thomas T. HigginsSVP and Chief
Historical Stock Chart
From Jul 2022 to Aug 2022
Historical Stock Chart
From Aug 2021 to Aug 2022